Key Takeaways
- • Blackstone and TPG are seeking valuations exceeding $4 billion for Hologic's surgical unit as part of their broader $18.3 billion acquisition of the medical technology firm completed in April 2026.
- • The acquisition of Hologic was structured at up to $79 per share, comprising $76 in cash and a contingent value right (CVR) worth up to $3, with total cash consideration of approximately $17.3 billion.
- • Hologic, a global leader in women's health diagnostics and medical imaging, transitioned to private ownership on April 7, 2026, with its common stock delisted from the Nasdaq Stock Market.
- • The deal was funded through a combination of equity and debt by the two private equity powerhouses, representing a major consolidation in the medical technology sector.
Summary
Blackstone and TPG have initiated a process to divest Hologic's surgical unit for a valuation exceeding $4 billion, according to reporting from the Financial Times. This divestiture activity follows the completion of their transformative $18.3 billion acquisition of Hologic, the medical technology firm specializing in women's health imaging, diagnostics, and surgical solutions. The take-private transaction closed on April 7, 2026, marking a significant shift of the publicly traded company into private equity ownership.
The original acquisition structure reflected substantial value creation potential for the investor consortium. Hologic shareholders received $76 per share in cash combined with a non-tradable contingent value right (CVR) with potential value of up to $3 per share, bringing the total consideration to $79 per share. The transaction required approximately $17.3 billion in cash consideration to equityholders, funded through a combination of equity capital and debt financing from Blackstone and TPG's respective platforms.
By offloading the surgical unit at a $4 billion-plus valuation, the sponsors are executing a portfolio optimization strategy characteristic of large-scale private equity acquisitions. This suggests management identified distinct value streams within Hologic's operations, with the surgical business representing a separable asset attractive to strategic or financial buyers. The delisting of Hologic's common stock from Nasdaq upon deal closure eliminated public market optionality, giving the sponsoring firms full operational and strategic control to implement restructuring and value-realization initiatives across the platform.
The original acquisition structure reflected substantial value creation potential for the investor consortium. Hologic shareholders received $76 per share in cash combined with a non-tradable contingent value right (CVR) with potential value of up to $3 per share, bringing the total consideration to $79 per share. The transaction required approximately $17.3 billion in cash consideration to equityholders, funded through a combination of equity capital and debt financing from Blackstone and TPG's respective platforms.
By offloading the surgical unit at a $4 billion-plus valuation, the sponsors are executing a portfolio optimization strategy characteristic of large-scale private equity acquisitions. This suggests management identified distinct value streams within Hologic's operations, with the surgical business representing a separable asset attractive to strategic or financial buyers. The delisting of Hologic's common stock from Nasdaq upon deal closure eliminated public market optionality, giving the sponsoring firms full operational and strategic control to implement restructuring and value-realization initiatives across the platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.